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Abstract
Background.
Benzodiazepines are commonly prescribed in prisons amidst the controversies surrounding their potential
role in causing behavioral disinhibition and aggressive behavior and their association with use and
tra cking of illicit and addictive substances. The present study aimed to 1) ascertain the relationship
between benzodiazepine prescription (including their dosage and duration of use) and aggressive
behavior and behavioral disinhibition in prison, and 2) investigate whether there was an association
between benzodiazepine prescription, (including their dosage and duration of use) and using and
tra cking illicit and addictive substances during imprisonment.
Methods.
Data were extracted from the electronic database of an “open” Swiss prison (n = 1,379) over a  ve-year
period (2010–2015). Measures included benzodiazepine prescription (yes/no), duration of
benzodiazepine use and mean dosage, and punishable behaviors (physical and verbal aggression,
disinhibited but not directly aggressive behaviors, property damage or theft, substance-related offenses,
and rule transgression). Propensity score matching was used to assess the relationship between
benzodiazepine prescription and punishable behaviors. Logistic regressions were used to test the
relationship of benzodiazepine duration and dosage with punishable behaviors.
Results.
Benzodiazepine prescription (yes/no) was not signi cantly associated with punishable behaviors.
Detained persons taking benzodiazepines were not more likely to commit offenses involving illicit or
addictive substance use or tra cking, even when taking these medications in higher dosage and over a
longer period of time.
Conclusions.
Our  ndings suggest that access to benzodiazepines in the prison setting should be subject to the same
regulations as in the community and that prescribing benzodiazepines to detained persons is just as safe
as prescribing these medications to those who are not detained.
Introduction
Benzodiazepines (BZD) are one of the most widely prescribed drugs in WEIRD (Western, Educated,
Industrialized, Rich, and Democratic) countries [1–4]. They are mainly prescribed to treat sleep disorders,
anxiety disorders, epilepsy, and withdrawal from certain substances. Their use has been widely debated.
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On one hand, BZD act quickly, are very useful in acute settings, and are generally effective. On the other,
they have been associated with various adverse effects, including sedation, psychomotor and cognitive
impairment, falls and fractures in the elderly, and dependence [5, 6]. In addition, individuals with
substance use disorders frequently abuse BZD, which is harmful, especially when various illicit drugs and
opioids are combined with BZD [7]. In view of these problems, most treatment guidelines do not
recommend BZD as  rst-line treatment for anxiety and related disorders and suggest that they should
only be used short-term [8–10]. In contrast, several experts have recently pointed out that such
recommendations are based on little empirical evidence and that these guidelines do not adequately
re ect the risk-bene t ratio when using BZD [3, 4, 11–14].
If use of BZD is controversial in the general population, the situation is even more complex in prisons,
where they are commonly prescribed [15, 16]. First, substance use disorders are more common among
detained persons than in the general population [17], and smuggling and tra cking of drugs are frequent
in prisons around the world [18]. Considering the likelihood of BZD abuse in the context of substance use
disorders, it has been suggested that BZD should be entirely avoided or minimally prescribed in prisons
[15, 19–21]. However, this is problematic, because prisoners would be deprived of a valid therapeutic
option [2, 22].
Another crucial issue associated with prescribing BZD in prisons pertains to an increased risk of
behavioral disinhibition, resulting in aggressive behavior [1, 23]. There is a dearth of research on this topic
[24], and some studies suggest that the link between BZD use and heightened aggression may only apply
to short-acting BZD [25]. Furthermore, violent crime was associated with unusually high doses of BZD
[26], whereas there was no increase in impulsive behavior with therapeutic doses of BZD [27]. In a recent
study, Albrecht et al [28]. concluded that high BZD doses were not su cient to increase the risk of
violence. These disparate  ndings make it di cult to understand the role of BZD as a treatment option in
the prison setting.
In view of the aforementioned issues and controversies, the present study, conducted in a sample of
Swiss detained persons, had two main aims: 1) to ascertain the relationship between BZD prescription
and aggressive behavior and behavioral disinhibition in prison; we also aimed to assess the potential
effects of the dosage of BZD and duration of their use on aggression and behavioral inhibition during
imprisonment; and 2) to investigate whether BZD prescription was associated with using and tra cking
illicit and addictive substances.
Materials And Methods
Study design and participants
This retrospective, cross-sectional study was based on the data on 1,206 persons detained in Realta
prison, Kanton Grisons, Switzerland. This is an “open” prison (capacity of 120) for sentenced males who
work outside the prison and have up to 36 hours of leave per week. Data for the 2010–2015 period were
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extracted from the electronic prison database on 1,379 measures (some detained persons were
incarcerated multiple times). Approval for conducting the study was received from the Cantonal Research
Ethics Committee of Bern (no. 2016 − 01539).
Variables
1. 1. Socio-demographics. These include age and region of origin.
2. 2. Incarceration and offense variables. We recorded the length of incarceration (based on the dates
of admission and discharge) and offenses leading to imprisonment: violence-related offenses
(assaults, sexual crime, other kinds of violence); property-related offenses (theft, robbery, other
property offenses); substance-related offenses (violation of drug laws); and other offenses (arson,
justice obstruction, manslaughter, tra cking, violation of weapon laws).
3. 3. BZD prescription. We recorded whether or not detained persons were prescribed BZD during
imprisonment. For those who received BZD, duration (in days) of use and dosage (mean dosage
expressed as mg/day and converted into diazepam mg equivalents) of BZD were collected. The list
of BZD and diazepam mg equivalent conversion guidelines are provided in Supplementary Table 1.
4. 4. Other prescribed medications. We recorded whether detained persons were prescribed other
psychotropic medications (i.e., antidepressants, antipsychotics, methylphenidate, mood stabilizers, or
opioid agonists [including heroin used for therapeutic purposes]) and medications for any somatic
(non-psychiatric) condition.
5. 5. Punishable behaviors. Data on the type and frequency of detained persons’ punishable behaviors
were collected. These were classi ed into  ve categories: 1) physical and verbal aggression (assaults
and threats made against others), 2) disinhibited, but not directly aggressive behaviors (e.g.,
slamming doors, swearing), 3) property damage or theft, 4) substance-related offenses (alcohol or
illicit drug use or tra cking), and 5) rule transgression (e.g., smoking when not allowed, returning
from leave late). We made a binary quali cation (presence/absence) for each category.
Statistical analyses
We  rst computed descriptive statistics for all variables. Then, we tested whether punishable behaviors
were associated with BZD prescription.
In the  rst set of analyses, we used a propensity score matching to minimize the effect of confounding
factors and make it possible to compare individuals who received BZD with those who did not receive
them. This method is used to estimate the effect of a treatment when relying on observational data and
to address the fact that assignment to a treatment is not random. The propensity score matching aims to
mimic randomization by matching the treated and untreated groups on a set of predetermined
covariables. The propensity score was estimated using a probit regression predicting BZD prescription
and including the following factors: age, region of origin (Switzerland/not Switzerland), length of
incarceration, type of offense, use of any other psychotropic medication, and use of any medication for
somatic diseases. The balancing properties of the propensity score were satis ed. We then matched
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groups (BZD/no BZD) using nearest neighbor matching ( ll Mahalanobis), allowing multiple neighbors in
case of identical propensity scores. The average treatment effect on the treated (ATT) was computed for
each punishable behavior used as outcome (sanctions related to physical and verbal aggression,
disinhibited, but not directly aggressive behaviors, property damage or theft, substance-related offenses,
and rule transgression). Crude and matched associations (before/after propensity score matching) are
reported.
In the second set of analyses, we focused on detained persons who received BZD. We computed  ve
logistic regressions, using as predictors mean dosage and duration of BZD prescription and the same
outcomes as the  rst set of analyses. For all these models, we controlled for age, region of origin, length
of incarceration, type of offenses, use of any other psychotropic medication, and use of any medication
for somatic diseases.
For the propensity score analysis, we computed sensitivity analyses using other methods to match
groups (covariate adjustment, inverse probability weighting, and strati cation). For the second set of
analyses, we performed sensitivity analyses by using the maximum BZD dosage instead of the mean
dosage. We also conducted logistic regressions using mean dosage and duration of BZD use coded as
zero for detained persons without BZD prescription. Finally, we controlled for the effect of short- versus
long-acting BZD. In all cases, the  ndings were similar to those reported in the Results section.
Analyses were performed with Stata 15 (propensity score estimation: pscore with no imposition of
common support, propensity matching: psmatch2 with option “ties”).
Results
Descriptive statistics are reported in Table 1. The mean age of detained persons was 33.1 ± 10.4 years.
About a third (35.4%) came from Africa and another third (31.4%) from Western Europe. The mean
duration of incarceration was 125.1 days.
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Table 1
Descriptive statistics and bivariate analyses for socio-demographics, incarceration and offense variables,
other prescribed medications, and punishable behaviors.
Variables Whole
sample
Yes (n = 
293)
No (n = 
1,086)
Socio-demographics      
  Age1 33.1 (10.4) 35.4 (9.8) 32.5 (10.5)
  Region of origin2,3      
    Asia 1.2 (17) 0.7 (2) 1.4 (15)
    Eastern Europe/Balkans 11.6 (160) 8.9 (26) 12.3 (134)
    Eastern, Central & South Africa 4.1 (57) 1.4 (4) 4.9 (53)
    Latin America 1.7 (23) 1.7 (5) 1.7 (18)
    Middle East 6.7 (93) 4.8 (14) 7.3 (79)
    North Africa 19.2 (265) 21.8 (64) 18.5 (201)
    Switzerland 24.4 (337) 37.2 (109) 21.0 (228)
    Western Africa 12.0 (166) 3.1 (9) 14.5 (157)
    Western Europe 7.0 (96) 6.8 (20) 7.0 (76)
    Unknow/unveri ed 12.0 (165) 13.7 (40) 11.5 (125)
Prison variables      
  Length of incarceration (days)1 125.1
(177.4)
157.3
(171.6)
116.4
(178.1)
  Type of offense3      
    Violence2 13.1 (180) 15.4 (45) 12.4 (135)
    Property2 38.7 (533) 54.6 (160) 34.4 (373)
    Substance2 19.4 (267) 25.3 (74) 17.8 (193)
1 Means and standard deviations.
2 Percentages and n.
3 There were 165 missing values for the region of origin (12.0%) and 40 missing values for type of
offenses (2.9%).
4 Reported for participants with BZD prescription (n = 290).
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Variables Whole
sample
Yes (n = 
293)
No (n = 
1,086)
    Other2 60.0 (827) 51.2 (150) 62.3 (677)
Medical information      
  Benzodiazepine      
    Prescription2 21.3 (293) - -
    Duration (no. of days)1,4 91.5 (7.0) - -
    Mean daily dosage (mg/Diazepam
equivalent)1,4
24.0 (25.0) - -
  Prescription of other psychotropic medications    
    Any2 25.0 (345) 68.3 (200) 13.4 (145)
    Antidepressant2 11.8 /163) 34.5 (101) 5.7 (62)
    Antipsychotic2 15.7 (217) 43.3 (127) 8.3 (90)
    Methylphenidate2 2.9 (27) 7.2 (21) 0.6 (6)
    Mood stabilizers2 1.5 (21) 3.8 (11) 0.9 (10)
    Opioid antagonist2 4.9 (68) 16.0 (47) 1.9 (21)
    Other2 0.9 (13) 3.1 (9) 0.4 (4)
  Any medication for somatic disease2 32.4 (447) 56.3 (165) 26.0 (282)
Sanctions      
  Physical and verbal aggression2 5.9 (81) 8.5 (25) 5.2 (56)
  Disinhibited but not directly aggressive behavior2 4.7 (65) 7.9 (23) 3.9 (42)
  Property damage or theft2 2.8 (38) 3.8 (11) 2.5 (27)
1 Means and standard deviations.
2 Percentages and n.
3 There were 165 missing values for the region of origin (12.0%) and 40 missing values for type of
offenses (2.9%).
4 Reported for participants with BZD prescription (n = 290).
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Variables Whole
sample
Yes (n = 
293)
No (n = 
1,086)
  Substance-related offenses2 11.7 (161) 19.1 (56) 9.7 (105)
  Rule transgression2 23.4 (323) 31.7 (93) 21.2 (230)
1 Means and standard deviations.
2 Percentages and n.
3 There were 165 missing values for the region of origin (12.0%) and 40 missing values for type of
offenses (2.9%).
4 Reported for participants with BZD prescription (n = 290).
A total of 293 (21.3%) detained persons were prescribed BZD during their incarceration (mean duration of
BZD use = 91.5 days, mean dosage = 24.0 mg/day diazepam equivalents).
The most common type of punishable behavior was rule transgression (323 instances or 23.4% of the
total sample), followed by substance-related offenses (161; 11.7%), physical and verbal aggression (81;
5.9%), disinhibited, but not directly aggressive behaviors (65; 4.7%), and property damage or theft (38;
2.8%).
In the analyses of the unmatched sample, detained persons with and without BZD prescription were
signi cantly different in terms of the factors included in the propensity score and outcomes (left panel of
Table 2). In the matched sample, there was no signi cant difference on any factor included in the
propensity score (right panel of Table 2). Thus, BZD prescription was not signi cantly associated with
any kind of punishable behavior.
Page 10/16
Table 2
Associations of factors and outcomes with BZD prescription in a sample with and without propensity
score matching
    Sample without propensity
score matching
Sample with propensity
score matching
    BZD No BZD p BZD No BZD p
    n = 293 n = 1,086   n = 253 n = 150  
Variables included in the propensity
score
           
  Age1 35.59 32.47 < .001 35.59 35.59 .643
  Region of origin (ref.
Switzerland)2
0.43 0.24 < .001 0.43 0.46 .532
  Length of incarceration (no. of
days)1
158.30 115.37 < .001 158.30 134.51 .122
  Prescription of other
psychotropic medications2
0.67 0.14 < .001 0.67 0.67 .925
  Prescription of medication for
somatic disease2
0.55 0.25 < .001 0.55 0.54 .789
  Offence: violence2 0.15 0.13 .231 0.15 0.14 .616
  Offence: property2 0.53 0.33 < .001 0.53 0.56 .423
  Offence: substance2 0.25 0.18 .018 0.25 0.22 .464
  Offence: other2 0.52 0.62 .002 0.52 0.53 .722
Outcomes2            
  Physical and verbal aggression 0.08 0.05 .084 0.08 0.04 .194
  Disinhibited but not directly
aggressive behavior
0.17 0.10 .001 0.17 0.13 .390
  Property damage or theft 0.08 0.04 .001 0.08 0.07 .576
  Substance-related offenses 0.03 0.03 .617 0.03 0.02 .390
  Rule transgression 0.30 0.21 .003 0.30 0.24 .239
BZD: benzodiazepine.
1 Means are reported.
2 Proportions are reported.
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With regards to detained persons who were prescribed BZD, the mean dosage of BZD was not associated
with any kind of punishable behavior (Table 3). Duration of BZD prescription was signi cantly associated
only with disinhibited, but not directly aggressive behaviors (p = .011).
Table 3. Association between BZD dosage and duration of use and punishable behaviors (n=290).
DV BZD mean dosage (IV1) BZD duration (IV2)
coef. p-value coef. p-value
Physical and verbal aggression 0.001 .888 0.001 .847
Disinhibited but not directly aggressive behavior -0.021 .110 0.010 .011
Property damage or theft 0.010 .399 -0.005 .343
Substance-related offenses 0.003 .611 0.002 .291
Rule transgression 0.008 .171 0.001 .522
BZD: benzodiazepine, DV: dependent variable, IV: independent variable
Logistic models were adjusted for age, region of origin (Switzerland/not Switzerland), length of
incarceration, type of offenses, prescription of any other psychotropic medication, and prescription of any
medication for somatic diseases.
Discussion
The main aim of the present study was to investigate the effects of BZD prescription on aggressive
behaviors and behavioral disinhibition in a Swiss prison. When controlling for potentially confounding
variables, we did not  nd any association between BZD prescription and punishable behaviors that would
re ect an increase in aggressiveness or behavioral disinhibition. This suggests that control variables
might have captured a previous tendency towards aggressive behavior (re ected by the type of offenses)
and psychiatric disorders associated with aggressiveness or disinhibited behaviors (re ected by the
prescription of other psychotropic medications). This  nding is in line with studies showing that
therapeutic doses of BZD are not associated with heightened aggressive behavior [27, 28], but it is in
contrast to other research that reports an association between use of BZD and aggressive behavior [1,
23]. Importantly, we also found no association between the dosage of BZD and duration of their use and
almost all kinds of punishable behaviors.
The only signi cant result was that use of BZD for longer periods of time might increase the likelihood of
engaging in disinhibited, but not directly aggressive behaviors. However, the effect size of this  nding was
very small: with an increase in the duration of BZD use by one day, detained persons were 1.00 times
more likely to exhibit disinhibited, but not directly aggressive behaviors.
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The second aim of the study was to investigate whether BZD prescription was associated with using and
tra cking illicit or addictive substances during imprisonment. We found that detained persons taking
BZD were not more likely to commit offenses involving illicit or addictive substance use or tra cking.
This did not change when we examined the dosage and duration of BZD use, which suggests that taking
BZD even in higher dosages and over a longer period of time does not seem to lead to substance-related
offenses in the prison setting. This  nding has important implications because prescribing BZD in
prisons is often avoided on the grounds of their presumed greater abuse potential [19, 20]. However,
abuse of BZD usually occurs in individuals with a history of substance use disorders; without this history,
BZD may be administered safely even in higher dosages and for a relatively long period of time (on
average, three months in our sample), with no risk that such use would inevitably lead to other substance
abuse [29]. Our  ndings lend support to this notion in the prison setting.
Our study has also revealed other important  ndings about the use of BZD in the prison setting. The
proportion of detained persons who were prescribed BZD (21.3%) is by no means negligible. Moreover,
when compared with detained persons who were not prescribed BZD, those using BZD were also
prescribed signi cantly more often all other classes of psychotropic agents and medications for general
medical conditions, which suggests that they had more mental health and general medical problems. A
poorer mental and physical health of these detained persons indicates their greater need for adequate
healthcare.
Following the principle of the equality of care, prison populations should bene t from effective and
evidence-based treatments that are available in the community. In the context of our study, this means
that access to BZD in the prison setting should be subject to the same regulations as in the community [2,
22]. The same applies to other psychotropic medications, as well as psychological interventions for
mental disorders. It is important to acknowledge that there are very few alternatives to psychotropic
medications in the prison system [30] and that treatment of many mental health issues should not only
rely on medications such as BZD.
Limitations
This study has a number of limitations. First, it was based on associations and was conducted
retrospectively, which precludes us from making inferences about any causal relationship. Second,
punishable behaviors recorded by the prison administration were the only indicator of aggressive and
disinhibited behavior, and we had no access to any information about punishable behaviors that were
concealed or undetected. Future studies should be conducted prospectively and use instruments for
assessing irritability, anger, behavioral disinhibition and aggressiveness. Third, our  ndings are based on
a sample of male detained persons in a Swiss setting and it is uncertain to what extent they can be
applied to female detained persons in another country. Fourth, there were no data on psychiatric
diagnoses and reasons for prescribing BZD, which might have been helpful to better understand and
contextualize the risk of aggressive behavior and disinhibition. Finally, prescribing any medication does
Page 13/16
not necessarily mean that it will be taken as prescribed, and we have no way of knowing whether
detained persons were actually using BZD as prescribed.
Conclusion
Detained persons are a vulnerable population with a high burden of psychiatric and general medical
morbidity; they should receive appropriate, timely and evidence-based treatment without institutional
barriers to treatment access. Our  ndings make a signi cant contribution to the literature in terms of
suggesting that prescribing BZD to detained persons is just as safe as prescribing these medications to
those who are not detained. More speci cally, we did not  nd support for the notions that BZD increase
aggressive or disinhibited behavior in detained persons or that they increase the risk of substance abuse
in this population. As with other pharmacological agents, BZD should be used carefully and cautiously in
the prison setting, along with evidence-based psychological interventions.
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